Trump administration advances plan for peptide drugs favored by RFK Jr.
The advisers backed compounding access despite FDA scientists citing limited human data and possible liver damage, allergic reactions and tumor growth.
- On Thursday, the Department of Health and Human Services submitted an "interim access policy" to the White House, aiming to allow specialty pharmacies to produce certain experimental peptides.
- Earlier this year, Health and Human Services Secretary Robert F. Kennedy Jr. directed the FDA to reconsider restrictions, prompting a July advisory panel vote to ease regulations on six compounds, including BPC-157 and TB-500.
- FDA staff scientists warned the substances lack clinical evidence and pose risks like liver toxicity, contradicting proponents who characterize the access push as a matter of "medical freedom."
- Reports from users like Dylan Meetze and Dominik E. include severe adverse effects—migraines, fatigue, and muscle spasms—after taking peptides that influencers promote as safe for "body optimization."
- Major telehealth providers like Hims & Hers and Noom plan to offer these peptides if access is eased, entering a market Wall Street analysts estimate could be worth $3 billion.
43 Articles
43 Articles
RFK Jr.’s priority plan to put peptides in pharmacies pushed to White House
A requested policy for adopting an alternative medicine is slotted for approval pending permission from the White House. Following the sanction of six peptide drugs from the […]
FDA advances peptide push to White House
Presented by Coalition to Strengthen America’s Healthcare {beacon} Healthcare Healthcare The Big Story RFK Jr. advances peptide push The Food and Drug Administration (FDA) this week submitted a peptide “interim access policy” to the White House for review, according to a government filing, which would reportedly allow compounding pharmacies to temporarily produce and sell previously restricted…
US FDA takes step to change peptide compounding policy
Oct 15 (Reuters) - The US FDA on Thursday submitted a new policy change that could allow pharmacies to more easily compound certain peptides to the White House for consideration. Telehealth company Hims & Hers Health had previously said it plans to o...
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D24&w=64&q=75){kind=small}
Trump Administration Moves to Expand Access to Experimental Peptides Despite FDA Safety Concerns
Federal health officials are advancing a policy that could allow compounding pharmacies to produce popular experimental peptides, potentially expanding access to substances promoted for healing, ... The post Trump Administration Moves to Expand Access to Experimental Peptides Despite FDA Safety Concerns first appeared on [your]NEWS.
Coverage Details
Bias Distribution
- 45% of the sources lean Left
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D60&w=128&q=75)
Factuality
To view factuality data please Upgrade to Premium
